# Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial

> **NCT01201837** · PHASE2 · COMPLETED · sponsor: **Cerenis Therapeutics, SA** · enrollment: 507 (actual)

## Conditions studied

- Acute Coronary Syndrome

## Interventions

- **DRUG:** Placebo
- **DRUG:** CER-001

## Key facts

- **NCT ID:** NCT01201837
- **Lead sponsor:** Cerenis Therapeutics, SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2012-10
- **Final completion:** 2013-03
- **Target enrollment:** 507 (ACTUAL)
- **Last updated:** 2014-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01201837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01201837, "Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01201837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*